Impact of antiretroviral treatment on AIDS dementia: A longitudinal prospective event-related potential study

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 2, 1998, Pages 143-148

  Evers, Stefan ^a   Grotemeyer, Karl H ^a   Reichelt, Doris ^a   Lüttmann, Susanne ^a   Husstedt, Ingo W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Antiviral therapy; Encephalopathy; Event related potentials

Indexed keywords

ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032007047     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802010-00007     Document Type: Article

References (36)

1. Ho DD, Bredesden DE, Vinters HV, Daar ES. The acquired immunodeficiency syndrome (AIDS) dementia complex. Ann Intern Med 1989;111:400-10.
2. Price RW. Neurological complications of HIV infection. Lancet 1996;348:445-52.
3. Hall M, Whaley R, Robertson K, Hamby S, Wilkins J, Hall C. The correlation between neuropsychological and neuroanatomic change over time in asymptomatic HIV-1-infected individuals. Neurology 1996;46:1697-1702.
4. Newman SP, Lunn S, Harrison MJG. Do asymptomatic HIV-seropositive individuals show cognitive deficit? AIDS 1995;9: 1211-20.
5. Ragazzoni A, Grippo AS, Ghidini P, et al. Electrophysiological study of neurologically asymptomatic HIV1 seropositive patients. Acta Neurol Scand 1993;87:47-51.
6. Goodwin GM, Chiswick A, Egan V, St Clair D, Brettle RP. The Edinburgh cohort of HIV-positive drug users: auditory event-related potentials show progressive slowing in patients with Centers for Disease Control stage IV disease. AIDS 1990;4:1243-50.
7. Baldeweg T, Gruzelier JH, Catalan J, et al. Auditory and visual event-related potentials in a controlled investigation of HIV infection. Electroenceph Clin Neurophysiol 1993;88:356-68.
8. Schroeder MM, Handelsman L, Torres L, et al. Early and late cognitive event-related potentials mark stages of HIV-1 infection in the drug-user risk group. Biol Psychiatry 1994;35:54-69.
9. Birdsall HH, Ozluoglu LN, Lew HL, et al. Auditory P300 abnormalities and leukocyte activation in HIV infection. Otolaryngol Head Neck Surg 1994;110:53-9.
10. Egan VG, Chiswick A, Brettle RP, Goodwin GM. The Edinburgh cohort of HIV-positive drug users: the relationship between auditory P3 latency, cognitive function and self-rated mood. Psychol Med 1993;23:613-22.
11. Coburn KL, Moore NC, Katner HP et al. HIV and the brain: evidence of early involvement and progressive damage. Neuroreport 1992;3:539-41.
12. Jabbari B, Coats M, Salazar A, Martin A, Scherokman B, Laws WA. Longitudinal study of EEG and evoked potentials in neurologically asymptomatic HIV subjects. Electroenceph Clin Neurophysiol 1993;86:145-51.
13. Grotemeyer KH, Husstedt IW, Brundermann H, Busch H, Schlake HP, Zidek W. Event-related potentials in HIV-infected outpatients. AIDS Res Hum Retroviruses 1991;7:629-35.
14. Arendt G, Hefter H, Jablonowski H. Acoustically evoked event-related potentials in HIV-associated dementia. Electroenceph Clin Neurophysiol 1993;86:152-60.
15. Linnville SE. Brain-emitted event-related potentials recorded during rapid decision-making may be useful in monitoring the neuropathogenesis of the human immunodeficiency virus (HIV). Percept Mot Skills 1995;81:209-10.
16. Fein G, Biggins CA, MacKay S. Delayed latency of the event-related brain potential P3a component in HIV disease. Arch Neurol 1995;52:1109-18.
17. Handelsman L, Horvath T, Aronson M, et al. Auditory event-related potentials in HIV-1 infection: a study in the drug-user risk group. J Neuropsychiatre Clin Neurosci 1992;4:294-302.
18. Ollo C, Johnson R, Grafman J. Signs of cognitive change in HIV disease: an even-related brain potential study. Neurology 1991;41: 209-15.
19. Gil R, Breux JP, Neau JP, et al. Potentiels evoques cognitifs aux stades II et III de l'infection par le virus de l'immunodeficience humaine. Ann Med Interne Paris 1991;142:297-302.
20. Baldeweg T, Catalan J, Lovett E, Gruzelier J, Riccio M, Hawkins D. Long-term zidovudine reduces neurocognitive deficits on HIV-1 infection. AIDS 1995;9:589-96.
21. Arendt G, Hefter H, Nelles HW, Hilperath F, Strohmeyer G. Age-dependent decline in cognitive information processing of HIV positive individuals detected by event-related recordings. J Neurol Sci 1993;115:223-9.
22. Connolly S, Manji H, McAllister RH, et al. Long-latency event-related potentials in asymptomatic human immunodeficiency type 1 infection. Ann Neurol 1994;35:189-96.
23. McAllister RH, Herns MV, Harrison MJ, et al. Neurological and neuropsychological performance in HIV seropositive men without symptoms. J Neurol Neurosurg Psychiatry 1992;55:143-8.
24. Evers S, Husstedt IW, Lüttmann S, Bauer B, Grotemeyer KH. Event-related potentials in HIV infection. Arch Neurol 1996;53: 715-6.
25. Messenheimer JA, Robertson KR, Wilkins JW, Kalkowski JC, Hall CD. Event-related potentials in human immunodeficiency virus infection. Arch Neurol 1992;49:396-400.
26. Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Fass RJ. Change in neuropsychological performance in asymptomatic HIV infection: 1-year follow-up. AIDS 1993;7:1607-11.
27. Wilkie FL, Morgan R, Fletcher MA, et al. Cognition and immune function in HIV-1 infection. AIDS 1992;6:977-81.
28. Wilkie FL, Eisdorfer C, Morgan R, Loewenstein DA, Szapocznik J. Cognition in early human immunodeficiency virus infection. Arch Neurol 1990;47:433-40.
29. Perdices M, Cooper DA. Simple and choice reaction time in patients with human immunodeficiency virus infection. Ann Neurol 1989;25:460-7.
30. Karlsen NR, Reinvang I, Froland SS. Slowed reaction time in asymptomatic HIV-positive patients. Acta Neurol Scand 1992;86: 242-.
31. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-8.
32. Baldeweg T, Riccio M, Gruzelier J, et al. Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: a longitudinal placebo-controlled study. J Neurol Sci 1995;132:162-9.
33. Centers for Disease Control. 1993 revised classification system for HIV infection. MMWR 1992;41:(RR-17)1-19.
34. Goodin D, Desmedt J, Maurer K, Nuwer M. IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. Electroenceph Clin Neurophysiol 1994;91: 18-20.
35. Portegies P, de Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br Med J 1989;299:819-21.
36. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993;7:1581-7.